Pluristem Therapeutics (PSTI) receives FDA orphan status for aplastic anemia treatment
- ITC Holdings (ITC) to Review of Strategic Alternatives Including Sale
- Wall St. dips with health, consumer shares; gains for November
- Market Wrap: Pending Sales Edge Higher in Oct.; Yuan Added to IMF's SDR; Amazon Shows-off Drone Tech
- SunTrust's Bob Peck Highlights 10 Candidates to Replace Yahoo! (YHOO) CEO Marissa Mayer
- After-Hours Stock Movers 11/30: (HFFC) (BLOX) (MFRM) Higher; (NQ) (AMSG) (SSH) Lower (more...)
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) has received FDA orphan status for aplastic anemia treatment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Pacific Ethanol (PEIX) Shares Active; EPA Boosts Biofuel Mandate from Prior Proposal
- Baxalta (BXLT) Announces U.S. Launch of ADYNOVATE
- Younger Users Continue Eschewing Traditional Search for Social Media in Product Research - GWI
Create E-mail Alert Related CategoriesFDA, Insiders' Blog
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!